Barclays
TNDM icon

Barclays’s Tandem Diabetes Care TNDM Stock Holding History

Barclays’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.29M Sell
350,429
-70,807
-17% -$1.24M ﹤0.01% 1806
2026
Q1 		$8.08M Sell
421,236
-496,691
-54% -$10.8M ﹤0.01% 1562
2025
Q4 		$20.2M Sell
917,927
-272,200
-23% -$4.91M ﹤0.01% 1256
2025
Q3 		$14.4M Buy
1,190,127
+623,055
+110% +$8.43M ﹤0.01% 1410
2025
Q2 		$10.6M Buy
567,072
+53,066
+10% +$1.05M ﹤0.01% 1541
2025
Q1 		$9.85M Buy
514,006
+37,032
+8% +$1.08M ﹤0.01% 1418
2024
Q4 		$17.2M Buy
476,974
+245,909
+106% +$8.32M ﹤0.01% 1208
2024
Q3 		$9.8M Sell
231,065
-174,647
-43% -$7.4M ﹤0.01% 1503
2024
Q2 		$16.3M Buy
405,712
+355,915
+715% +$14.8M 0.01% 1007
2024
Q1 		$1.76M Buy
49,797
+147
+0.3% +$3.94K ﹤0.01% 2678
2023
Q4 		$1.47M Sell
49,650
-34,490
-41% -$715K ﹤0.01% 3155
2023
Q3 		$1.75M Buy
84,140
+18,025
+27% +$495K ﹤0.01% 1979
2023
Q2 		$1.62M Sell
66,115
-34,657
-34% -$1.11M ﹤0.01% 2019
2023
Q1 		$4.09M Buy
100,772
+13,514
+15% +$560K ﹤0.01% 1683
2022
Q4 		$3.92M Sell
87,258
-14,382
-14% -$651K ﹤0.01% 1791
2022
Q3 		$4.86M Sell
101,640
-9,967
-9% -$546K 0.01% 1181
2022
Q2 		$6.61M Buy
111,607
+5,556
+5% +$456K ﹤0.01% 1193
2022
Q1 		$12.3M Buy
106,051
+3,594
+4% +$420K 0.01% 843
2021
Q4 		$15.4M Sell
102,457
-23,876
-19% -$3.22M 0.01% 1053
2021
Q3 		$15.1M Buy
126,333
+6,056
+5% +$667K 0.01% 1005
2021
Q2 		$11.7M Sell
120,277
-11,344
-9% -$1.01M 0.01% 1134
2021
Q1 		$11.6M Buy
131,621
+35,625
+37% +$3.31M 0.01% 1023
2020
Q4 		$9.19M Buy
95,996
+10,217
+12% +$1.05M ﹤0.01% 1193
2020
Q3 		$9.74M Sell
85,779
-15,701
-15% -$1.65M 0.01% 1045
2020
Q2 		$10M Buy
101,480
+80,443
+382% +$6.42M 0.01% 962
2020
Q1 		$1.35M Sell
21,037
-77,584
-79% -$5.44M ﹤0.01% 2654
2019
Q4 		$5.88M Buy
98,621
+64,409
+188% +$3.97M ﹤0.01% 1841
2019
Q3 		$2.02M Sell
34,212
-10,324
-23% -$659K ﹤0.01% 2856
2019
Q2 		$2.87M Buy
44,536
+9,028
+25% +$583K ﹤0.01% 2482
2019
Q1 		$2.26M Sell
35,508
-6,054
-15% -$318K ﹤0.01% 2437
2018
Q4 		$1.58M Sell
41,562
-48,656
-54% -$1.72M ﹤0.01% 2647
2018
Q3 		$3.87M Buy
90,218
+32,444
+56% +$1.13M ﹤0.01% 2091
2018
Q2 		$1.27M Buy
57,774
+10,674
+23% +$131K ﹤0.01% 3011
2018
Q1 		$234K Buy
47,100
+20,300
+76% +$65.5K ﹤0.01% 4696
2017
Q4 		$63K Buy
+26,800
New +$84.2K ﹤0.01% 5603
2017
Q3 		– Sell
-1,369
Closed -$11K – 7045
2017
Q2 		$11K Sell
1,369
-1,820
-57% -$16.8K ﹤0.01% 6030
2017
Q1 		$38K Buy
3,189
+3,185
+79,625% +$69.6K ﹤0.01% 5486
2016
Q4 		$0 Sell
4
-9
-69% -$346 ﹤0.01% 6831
2016
Q3 		$1K Buy
+13
New +$948 ﹤0.01% 6446
2016
Q2 		– Sell
-480
Closed -$38K – 6633
2016
Q1 		$38K Buy
+480
New +$42K ﹤0.01% 4932
2015
Q4 		– Sell
-9
Closed -$1K – 6566
2015
Q3 		$1K Sell
9
-25
-74% -$2.91K ﹤0.01% 6601
2015
Q2 		$3K Buy
34
+5
+17% +$622 ﹤0.01% 6699
2015
Q1 		$4K Sell
29
-39
-57% -$5.07K ﹤0.01% 6701
2014
Q4 		$8K Sell
68
-57
-46% -$7.9K ﹤0.01% 6828
2014
Q3 		$16K Buy
125
+111
+793% +$15.5K ﹤0.01% 6632
2014
Q2 		$2K Sell
14
-22
-61% -$3.74K ﹤0.01% 7414
2014
Q1 		$8K Sell
36
-8
-18% -$2.04K ﹤0.01% 7033
2013
Q4 		$11K Buy
+44
New +$10.1K ﹤0.01% 6973

Other funds holding TNDM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Barclays's TNDM Position: Q2 2026 in Review

Barclays reduced its Tandem Diabetes Care (TNDM) stake by 17% in Q2 2026, selling an estimated $1.24M and leaving 350,429 shares worth $5.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1806.

Barclays first reported a position in TNDM in Q4 2013 and has held it in 48 quarters since. The position peaked at $20.2M in Q4 2025. 274 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.

  • Barclays held 350,429 shares of Tandem Diabetes Care worth $5.29M as of Q2 2026.
  • Barclays sold 70,807 Tandem Diabetes Care shares in Q2 2026, an estimated $1.24M.
  • Tandem Diabetes Care made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1806 holding.
  • Barclays first reported a position in Tandem Diabetes Care in Q4 2013 and has held it in 48 quarters since.
  • Barclays's Tandem Diabetes Care position peaked at $20.2M in Q4 2025.
  • 274 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.